Free provider profile
STEPHEN RAMONDINO, MD
NPI 1942388657
Individual
Psychiatry & Neurology, Psychiatry
Active registration
Save to rep workspaceNPI registry Registry record
Source: CMS NPPES registry, updated continuously. This record was last updated 2018-03-26.
576 HARTNELL ST.#300, MONTEREY, CA, 93940
831-625-4600
Single practice location
Enumerated 2006-11-01
- — Registration is active in NPPES.
- — Individual clinician record — reachable, but usually not the buyer.
- — Practice phone number is published.
- — Full street address on file for route planning.
- — 1 payer identifiers on file — enrolled with payers.
- — Record last updated 8 years ago.
Medicare Part D prescribing
Source: CMS Medicare Part D Prescribers by Provider, most recent public year.
Part D claims
1,390
Medicare patients
89
Part D drug cost
$579,001
Brand-name share
16%
of this prescriber's Part D claims
| Drug | Claims | Medicare cost |
|---|---|---|
| Austedo (Deutetrabenazine) | 32 | $321,744 |
| Vraylar (Cariprazine Hcl) | 33 | $48,895 |
| Spravato (Esketamine Hcl) | 38 | $47,257 |
| Auvelity (Dextromethorphan Hbr/Bupropion) | 21 | $26,994 |
| Belsomra (Suvorexant) | 49 | $21,577 |
| Trintellix (Vortioxetine Hydrobromide) | 17 | $7,877 |
| Vilazodone Hcl (Vilazodone Hcl) | 29 | $3,869 |
| Eszopiclone (Eszopiclone) | 53 | $1,616 |
Want their full drug mix and peer benchmark? Run the free Part D prescriber lookup.
Spravato (esketamine) Medicare billing
Source: CMS Medicare Part B fee-for-service, HCPCS G2082/G2083.
2024187 sessions · 15 patients · $203,927
Full Spravato label-compliance detail — sessions per patient against the FDA label, risk flags and year-over-year trend.
- Registry data comes straight from CMS NPPES, which lists registration, not activity — a listed practice may have moved or closed.
- Part D covers Medicare prescription drug enrollees only. Commercial, Medicaid and cash-pay prescribing is not included, so these figures are a floor on real volume, not the whole picture.
- CMS publishes the Part D file annually, roughly two years behind the prescribing year. Drugs with 10 or fewer claims are suppressed.